Targeting Tumor Microenvironment in Cancer: Promises and Challenges
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (20 July 2024) | Viewed by 4112
Special Issue Editors
Interests: stem cell biology; regenerative medicine
Interests: cancer epigenetics; anticancer drugs
Special Issue Information
Dear Colleagues,
The tumor microenvironment (TME) is the environment surrounding a tumor, and it plays a critical role in cancer progression. The TME is made up of a variety of cells, including tumor cells, immune cells, and stromal cells. These cells interact with each other in a complex way to create an environment that is favorable for tumor growth and metastasis. Traditional cancer treatments, such as chemotherapy and radiation therapy, can be effective at killing tumor cells. However, these treatments can also damage healthy cells, and they often lead to the recurrence of the cancer. By targeting the TME, it is possible to disrupt the interactions between tumor cells and the other cells in the microenvironment, preventing tumor growth and metastasis. This targeting is achieved via drugs that target specific molecules (e.g., growth factors and immune cells). Another approach to targeting the TME is to use cell-based therapies, where engineered immune cells could be used to attack tumor cells. This Special Issue will provide an overview of the tumor microenvironment and the different ways to target it. The Special Issue will also discuss the challenges and opportunities associated with TME-targeted therapy.
Prof. Dr. Ahmed H.K. El-Hashash
Prof. Dr. Hussein Sabit
Dr. Borros Michael Arneth
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeting tumor microenvironment
- TME-targeted therapy
- Cancer
- tumor microenvironment (TME)
- cancer progression
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
